The Biotechnology Innovation Organization says a new report from Initiative for Medicines, Access & Knowledge (I-MAK) claiming the average patent life for the top 12 U.S. drugs is 38 years -- nearly double the 20 years the U.S. system promises -- “includes numerous flaws that are designed to portray a distorted view of the biopharmaceutical industry.” Stakeholders from both parties have acknowledged so-called patent thickets keep drugs off the market -- and one need not look beyond the current biosimilar...